6533b829fe1ef96bd128a248

RESEARCH PRODUCT

Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee

Wendy B. LondonMichael D. HogartyRie SuganumaA. Thomas LookClaudio GambiniArlene NaranjoHideki SanoCatherine CullinaneLarry WangHiroyuki ShimadaGabriele AmannEmanuele S.g. D'amoreJason A. JarzembowskiJohn M. MarisRobert C. SeegerKlaus BeiskeSusan L. CohnSamuel NavarroMichel PeuchmaurJulie M. Gastier-fosterVijay V. JoshiJulie R. Park

subject

OncologyPathologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseNeuroblastic TumorN-Myc Proto-Oncogene ProteinGenotype phenotypePeripheralOncologyNeuroblastomaInternal medicinePediatrics Perinatology and Child HealthMycn amplificationMedicineImmunohistochemistrybusinessneoplasms

description

Background Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children’s Cancer Group and Children’s Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotype-phenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis).

yearjournalcountryeditionlanguage
2012-06-28Pediatric Blood & Cancer
https://doi.org/10.1002/pbc.24238